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Complete Inactivation of the TSC2 Gene Leads to
Formation of Hamartomas
To the Editor:
Tuberous sclerosis complex (TSC [MIM 191092]), a
dominantly inherited disease with a prevalence of 1/
6,700 (Sampson et al. 1989; Osborne et al. 1991; Ahlsen
et al. 1994) is characterized by hamartomas found in
almost every organ system and by malignancy in some
organ systems. Two genetic loci have been identified: the
TSC1 gene, on chromosome 9q34.3, and TSC2, on chro-
mosome 16p13.3 (The European Chromosome 16 Tu-
berous Sclerosis Consortium 1993; van Slegtenhorst et
al. 1997). A tumor-suppressor function has been sug-
gested for TSC2 by loss of heterozygosity (LOH) in ha-
martomas (Green et al. 1994; Henske et al. 1995, 1996;
Carbonara et al. 1996; Sepp et al. 1996). Thus far, no
reports have demonstrated mutations in both alleles of
the TSC2 gene in hamartomas in humans. Further evi-
dence of a tumor-suppressor function for TSC2 comes
from the Eker rat, a naturally occurring model of tu-
morigenesis. The Eker rat has been determined to have
a germline mutation in the Tsc2 gene (the homolog of
the TSC2 gene in humans) (Yeung et al. 1994; Kobayashi
et al. 1995; Kubo et al. 1995). LOH and second somatic
hit studies of the Tsc2 gene have been reported in 33%
of spontaneous or chemically induced Eker rat renal-cell
carcinoma (RCC) lines (Kobayashi et al. 1997). The
mechanism for cell transformation in humans is ex-
pected to be different from that in rats, because RCCs
are detectable in 100% of Eker rats by age 1 year,
whereas only a small percentage (2.5%) of humans with
TSC develop RCCs (Eker et al. 1981; Bjornsson et al.
1996; Cook et al. 1996; Al-Saleem et al. 1998). We
collected a variety of hamartomas—angiomyolipomas
(AMLs) from three patients, cortical tubers from two
patients, and facial angiofibromas (FAs) from one pa-
tient—from patients in whom the germline TSC2 mu-
tation had been identified (Au et al. 1998). These tissues
were tested for the second hit by Southern blotting, with
the TSC2 gene as a probe, and by LOH studies of the
TSC2 gene and surrounding markers. The second hit for
the TSC2 gene was detected in AMLs from two inde-
pendent patients and in FAs from another patient, pro-
viding direct evidence that mutations in both alleles are
required for tumorigenesis in humans affected by TSC
(Knudson 1971).
The patients in this study have been described else-
where (Au et al. 1998). All were diagnosed with TSC
according to standard criteria by Roach et al. (1998).
Informed consent approved by the institutional review
boards at The University of Texas Medical School–
Houston, The University of Texas SouthwesternMedical
School, and the Scottish Rite Hospital in Dallas was
obtained. Tissue samples collected included 6 AMLs
from the right kidney and 1 AML from the left kidney
of patient HOU23-01, 1 AML from patient HOU23-03,
14 AMLs from patient TS94-104, 3 FAs from patient
TS93-41, and 1 cortical tuber each from patients TS93-
14 and TS94-53.
DNA from the blood lymphocytes of the patients was
prepared as previously described. Small samples of tissue
were removed from the well-circumscribed tumors at the
time of surgery. Fresh tumor tissue weighing ∼0.2 g (or
the whole tumor, if it was !0.2 g) was dissected, minced,
and rinsed with phosphate-buffered saline to remove red
blood cells. The minced tissue was digested with 1 mg
proteinase K/ml in 10 ml of lysis buffer, with remaining
processing being the same as that for lymphocyte DNA.
Individual TSC2 gene exons containing the germline
mutation were amplified by polymerase chain reaction
(PCR) from lymphocytic DNA and from the tumor
DNA, as described elsewhere (Au et al. 1998). The in-
tragenic polymorphic EcoRV marker in exon 40 was
tested in informative cases (Au et al. 1997). Chromo-
somal markers (D16S525, KG8, and D16S665) flanking
the TSC2 gene were tested as described elsewhere (Peral
et al. 1994; Shen et al. 1994; Snarey et al. 1994).
Southern analyses were performed as described else-
where (Au et al. 1997). The TSC2 gene fragments were
identified sequentially, with different segments of the
TSC2 cDNA used as probes. One probe, consisting of
nucleotides 1–1197 of the TSC2 cDNA, detects two ad-
jacent BamHI fragments of 15 kb (exons 1–8) and 7 kb
(exons 9–14) and a 15-kb HindIII fragment (exons
1–11) of the TSC2 gene. Another probe used for veri-
fication, consisting of nucleotides 1369–2689 of the
TSC2 cDNA, detects two adjacent BamHI frag-
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Table 1
Summary of LOH Studies
PATIENT
AND
TUMOR
SAMPLE
LOH FINDINGS FOR GERMLINE MUTATION
D16S525
Exon 18
(dl C2070)
Exon 24
(insC 2779)
Exon 30
(dup3611-27)
Exon 36
(dl4770-2)
Exon 37
(A4859T)
Exon 40
(EcoRV) KG8 D16S665
HOU23-01:
1T LOH ) LOH ) ) ) LOH NI LOH
rT1 LOH ) LOH ) ) ) LOH NI LOH
rT2 LOH ) LOH ) ) ) LOH NI LOH
rT3 H ) H ) ) ) H NI H
rT4 H ) H ) ) ) H NI H
rT5 LOH ) LOH ) ) ) LOH NI LOH
rT6 LOH ) LOH ) ) ) LOH NI LOH
HOU23-03:
T H ) H ) ) ) H NI H
TS94-104:
T1 NI LOH ) ) ) ) NI LOH LOH
T2 NI LOH ) ) ) ) NI LOH LOH
T3 NI LOH ) ) ) ) NI LOH LOH
T4 NI LOH ) ) ) ) NI LOH LOH
T5 NI LOH ) ) ) ) NI LOH LOH
T6 NI LOH ) ) ) ) NI LOH LOH
T7 NI LOH ) ) ) ) NI LOH LOH
T8 NI LOH ) ) ) ) NI LOH LOH
T9 NI LOH ) ) ) ) NI LOH LOH
T10 NI LOH ) ) ) ) NI LOH LOH
T11 NI LOH ) ) ) ) NI LOH LOH
T12 NI LOH ) ) ) ) NI LOH LOH
T13 NI LOH ) ) ) ) NI LOH LOH
T14 NI LOH ) ) ) ) NI LOH LOH
TS93-41:
FA1 H ) ) H ) ) NI H NI
FA2 H ) ) H ) ) NI H NI
FA3 H ) ) H ) ) NI H NI
TS93-14:
T H ) ) ) H ) H H H
TS94-53:
T NI ) ) ) ) H H NI H
NOTE.—NI = noninformative; ellipsis ()) = not applicable; and H = maintainance of heterozygosity.
ments—of 7 kb (exons 9–14) and 14 kb (exons 15–
24)—and a 15-kb HindIII fragment.
In all cases, the TSC2 allele with the germline muta-
tion was retained in the tumor DNA (table 1). When
flanking markers D16S525, KG8, and D16S665 and an
intragenic marker, TSC2 exon 40 EcoRV, were used,
LOH was not detected in DNA from the one AML from
patient HOU23-03, from the three FAs from patient
TS93-41, or from the two cortical tubers from patients
TS93-14 and TS94-53 (data not shown).
Seven samples of tissue from AMLs were available
from patient HOU23-01: six from the right kidney and
one from the left kidney. The TSC2 allele carrying the
germline mutation was retained in all seven tumors (ta-
ble 1). Five of the seven AMLs (four from the right and
one from the left) showed decreased intensity for one
allele with markers D16S525, TSC2 exon 40 EcoRV,
and D16S665, indicating LOH for some cells from those
samples (fig. 1). The alleles with decreased intensity for
the markers were the same in all five tumors (lT, rT1,
rT2, rT5, and rT6) and were derived from the chro-
mosome harboring the wild-type TSC2 allele (Rose et
al. 1999). We concluded that the second hit in these
tumors involved deletion of the complete wild-type
TSC2 allele, leaving the nonfunctional germline mutated
copy in the tumor. Extent of loss along the chromosome
was not determined. In the two AMLs from the right
kidney that did not show LOH, Southern blotting with
the full-length TSC2 cDNA used as a probe did not
reveal aberrant banding patterns (data not shown), im-
plying that large deletion or rearrangement of the wild-
type TSC2 allele is not the second hit in these two tumors
(rT3 and rT4, from patient HOU23-01).
All 14 AMLs of patient TS94-104 showed loss of the
normal copy of exon 18 while retaining the 1-bp smaller
mutant copy. The markers KG8 and D16S665 also ex-
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Figure 1 Testing of DNA samples from family HOU23, includ-
ing members HOU23-04 (unaffected father), HOU23-05 (unaffected
mother), HOU23-02 (unaffected child), HOU23-03 (affected child),
and HOU23-01 (affected child), as depicted on pedigree shown above
gels. The family represents an example of germline mosaicism, details
of which are reported elsewhere (Rose et al. 1999). Individual lanes
are labeled to indicate tissue from which DNA was extracted: B =
blood lymphocytes, T = AML sample fromHOU23-03, lT = left kidney
AML, rT1–rT6 = six individual right-kidney AML samples, and rNK
= right-kidney normal tissue from HOU23-01. Decrease in intensity
of bands indicating loss of the wild-type TSC2 allele in some cells of
the AMLs from patient HOU23-01 are observed in A–C. A, Marker
D16S525 is located ∼95 kb telomeric to the 5′ end of TSC2. Both
HOU23-01 and HOU23-03 are heterozygous, with alleles of 149 bp
and 161 bp present. The 161-bp allele was significantly reduced in the
lT, rT1, rT2, rT5, and rT6 of HOU23-01, whereas the 149-bp and
161-bp alleles were of equal intensity in rT3 or rT4 of HOU23-01
and in the AML (T) from HOU23-03. B, Patients were informative
for the EcoRV polymorphism in exon 40 of TSC2, with heterozygotes
showing three bands at 579, 389, and 190 bp, respectively. Decrease
in the intensity of the wild-type allele was found in the same AML
DNAs (lT, rT1, rT2, rT5, and rT6) as in A, indicating LOH for the
wild-type allele in some cells from which the DNA was extracted. C,
The marker D16S665 is located ∼75 kb from the 3′ end of TSC2. The
father (HOU23-04) is heterozygous for the marker, with alleles of 142
and 88 bp, and the mother is homozygous for the 124-bp allele. The
results showed the same five AMLs (lT, rT1, rT2, rT5, and rT6) with
decreased intensity of the paternal 88-bp allele, while retaining the
maternal 124-bp allele. The paternal 142-bp allele is not inherited by
any of the offspring in the family.
hibited LOH in DNA from these tumors (table 1). The
somatic events led to a minimal deletion, from exons
18–41 of the patient’s wild-type TSC2 allele, in these
AMLs. Markers TSC2 exon 40 and D16S525 were not
informative for this patient (table 1). Because of the lack
of informativeness of markers, we were unable to de-
termine whether the LOH differed among samples—that
is, whether they represented one very large (clonal) tu-
mor or multiple tumors.
The three FAs obtained from patient TS93-41 showed
no decreased intensity for any of the markers tested;
however, junction fragments were detected by Southern
blotting. DNA extracted from both FA1 and FA2 of
patient TS93-41 revealed 7.5-kb junction fragments de-
tectable by restriction enzymeHindIII (fig. 2A). Junction
fragments of ∼11 kb were detected after digestion with
BamHI (data not shown). Three additional probes—
nucleotides 1–1197 (exons 1–11), nucleotides 1369–
2689 (exons 12–23), and a probe containing only exon
3—were tested to define the deletion (data not shown).
On the basis of the published restriction map of the
TSC2 genomic DNA (The European Chromosome 16
Tuberous Sclerosis Consortium 1993), the missing por-
tion of the gene is roughly 22–25 kb in size and extends
from just beyond exon 3 to exon 25 (fig. 2B).
Our study confirmed the germline and defined the so-
matic second hits of the TSC2 gene in AMLs and FAs
from three independent patients with TSC. These ob-
servations provide direct proof of tumor-suppressor
function for the TSC2 gene, in accordance with Knud-
son’s two-hit hypothesis, in the formation of hamarto-
mas in humans. The studies indicate that the second hit
in these tumors involved deletion of the complete wild-
type TSC2 allele, leaving the nonfunctional germlinemu-
tated copy. Another group has recently reported both
hits in a malignant islet-cell tumor from a patient with
TSC with a germline mutation identified in the TSC2
gene (Verhoef et al. 1999).
An earlier report (Sampson et al. 1997) found a critical
role for the PKD1 gene in the etiology of severe renal
disease in some patients with TSC. Sampson’s patients
exhibited a mixed phenotype that included features of
TSC and polycystic kidney disease (PKD). Our three
patients (HOU23-01, HOU23-03, and TS94-104) had
serious renal disease resulting primarily from angiom-
yolipomas with only minor cysts present; therefore, their
symptoms are not consistent with PKD. The three pa-
tients had single-base-pair insertion or deletion muta-
tions, all of which are predicted to cause premature ter-
mination of tuberin, approximately midway (exons 18
and 24) through the open reading frame of the TSC2
gene. We demonstrate that intragenic TSC2 mutations,
without involvement of the PKD1 gene, can result in a
life-threatening renal phenotype in patients with TSC.
Two of the AML DNAs (rT3 and rT4) from HOU23-
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Figure 2 An intragenic deletion of TSC2 is the second (somatic)
mutation in two FAs from patient TS93-41. Studies using markers
within and flanking TSC2 showed no evidence for LOH in the three
FAs obtained. A, Southern analysis of DNA from two FAs (FA1 and
FA2), performed bymeans of a TSC2 cDNA probe spanningnucleotide
1–1197, revealed junction fragments of ∼7.5 kbwithHindIII digestion.
No junction fragment was detected with the lymphocyte DNA (lane
B), even when a much higher (approximately fivefold) concentration
of DNA was used. B, Diagram illustrating probes tested, restriction
map for BamHI and HindIII of the TSC2 gene, predicted fragment
sizes, and approximate size and location of deletion.
01 did not reveal an aberrant banding pattern on South-
ern blots (not shown), and no LOH of the testedmarkers
was evident; therefore, deletion of the entire wild-type
TSC2 allele was not the second event leading to for-
mation of these two tumors. More subtle, undefinedmu-
tations are likely the cause of the loss of function of the
second allele in these tumors.
Previous attempts to search for LOH of markers
within and around the TSC2 gene in facial angiofibro-
mas have been unsuccessful (Henske et al. 1996). Our
success in detecting junction fragments relied on the rel-
ative abundance of DNA we could extract from the two
FAs available and on the use of the two smaller TSC2
cDNA probes (1–1197 and 1369–2689) to detect the
specific TSC2 genomic fragments in Southern analyses.
The relatively small amount of DNA represented by the
junction fragments in these FAs suggests that the tumor
cells were in low abundance. A slight reduction of one
of the heterozygous alleles of these markers would be
difficult to detect. Previous failure to demonstrate LOH
in TSC brain lesions could reflect the same difficulties
observed in FAs. Perhaps tumorigenesis for FAs and
brain tumors does not require the extensive LOH seen
in AMLs.
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